Valuation: Coya Therapeutics, Inc.

Market Cap 110M 94.95M 89.01M 81.16M 153M 10.45B 155M 1.05B 409M 5.23B 411M 402M 17.46B P/E 2026 *
-3.51x
P/E 2027 * -3.38x
Enterprise Value 110M 94.95M 89.01M 81.16M 153M 10.45B 155M 1.05B 409M 5.23B 411M 402M 17.46B EV / Sales 2026 *
90.2x
EV / Sales 2027 * 22.1x
Free-Float
83.27%
Yield 2026 *
-
Yield 2027 * -
1 day-0.43%
1 week+1.97%
Current month+11.46%
1 month-3.81%
3 months+2.86%
6 months-0.85%
Current year-19.48%
1 week 4.52
Extreme 4.52
4.85
1 month 3.86
Extreme 3.855
4.98
Current year 3.71
Extreme 3.7101
6.21
1 year 3.71
Extreme 3.7101
7.75
3 years 3.21
Extreme 3.21
10.69
5 years 3.21
Extreme 3.21
10.69
10 years 3.21
Extreme 3.21
10.69
Manager TitleAgeSince
Chief Executive Officer 57 2024-10-31
President 67 2023-07-16
Director of Finance/CFO 65 2022-03-29
Director TitleAgeSince
Director/Board Member 58 2021-02-28
Director/Board Member 67 2021-05-24
Director/Board Member 64 2021-05-31
Date Insider Type Main position Quantity % Market Cap.
1/22/26 Free

Chief Financial Officer

140,041 0.6693%
1/22/26 Free

Chief Executive Officer

15,257 0.0729%
1/22/26 Free

Chairperson

140,041 0.6693%
Change 5-day change 1-year change 3-year change Capi.($)
-0.43%+1.97%-24.68%+38.17% 110M
+1.17%+1.09%+4.03%+15.74% 48.72B
-1.59%+2.12%+460.02%+573.56% 43.99B
-0.85%+7.95%+15.77%+80.09% 40.82B
-0.08%+3.91%+26.96%+9.86% 39.79B
0.00%+3.59%+20.51%+48.00% 32.7B
-3.61%-1.45% - - 16.84B
-2.52%-0.52%+24.35%+118.05% 16.66B
+0.72%+0.31%+4.94%+21.70% 13.95B
-1.09%+5.94%+81.46%+31.15% 13.58B
Average -0.83%+2.09%+68.15%+104.04% 26.72B
Weighted average by Cap. -0.59%+2.44%+97.48%+135.55%

Financials

2026 *2027 *
Net sales 1.21M 1.05M 986K 899K 1.69M 116M 1.72M 11.61M 4.53M 58M 4.56M 4.46M 193M 4.96M 4.3M 4.03M 3.68M 6.92M 474M 7.03M 47.47M 18.53M 237M 18.63M 18.22M 791M
Net income -29.32M -25.41M -23.82M -21.72M -40.87M -2.8B -41.53M -281M -110M -1.4B -110M -108M -4.67B -32.06M -27.79M -26.05M -23.75M -44.69M -3.06B -45.4M -307M -120M -1.53B -120M -118M -5.11B
Net Debt - -
Logo Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.
Employees
8
Date Price Change Volume
26-08-13 US$4.670 -0.43% 97,444
26-08-12 US$4.690 -2.29% 85,589
26-08-11 US$4.800 +3.45% 130,176
26-08-10 US$4.640 -3.53% 181,086
26-08-07 US$4.810 +5.02% 141,840
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.670USD
Average target price
15.21USD
Spread / Average Target
+225.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COYA Stock